ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial
Status:
Terminated
Trial end date:
2016-03-16
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to test whether anticoagulation with bivalirudin
results in fewer major bleeding complications compared with unfractionated heparin (UFH) in
participants undergoing peripheral endovascular interventions (PEI). The secondary objective
is to test whether there were potential benefits from bivalirudin therapy on other clinically
important events such as death, myocardial infarction (MI), stroke and/or transient ischemic
attack (TIA), amputation, unplanned repeat revascularization (URV), and minor bleeding, as
well as potential economic benefits that may result from improved clinical outcomes.